cabozantinib
Cabometyx
Pharmaceutical company: Exelixis, Inc.
NEW INDICATION & DOSAGE
Previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors (Cabometyx only)
Adults and children ages 12 and older weighing 40 kg or more: 60 mg PO daily until disease progression or unacceptable toxicity.
Children ages 12 and older weighing less than 40 kg: 40 mg PO daily until disease progression or unacceptable toxicity.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
durvalumab
Imfinzi
Pharmaceutical company: AstraZeneca
NEW INDICATION & DOSAGE
Muscle-invasive bladder cancer
Adults weighing 30 kg or more: 1,500 mg IV every 3 weeks in combination with gemcitabine and cisplatin for 4 cycles prior to surgery, followed by 1,500 mg IV every 4 weeks as a single agent for up to 8 cycles after surgery.
Adults weighing less than 30 kg: 20 mg/kg IV every 3 weeks in combination with gemcitabine and cisplatin for 4 cycles prior to surgery, followed by 20 mg/kg IV every 4 weeks as a single agent for up to 8 cycles after surgery.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
eculizumab
Soliris
Pharmaceutical company: Alexion Pharmaceuticals
NEW INDICATION & DOSAGE
Generalized myasthenia gravis in patients who are anti-acetylcholine receptor antibody positive
Children ages 6 and older weighing 40 kg or more: 900 mg IV once every 7 days for 4 weeks, then 1,200 mg IV 7 days later (week 5), followed by 1,200 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 30 to less than 40 kg: 600 mg IV once every 7 days for 2 weeks, then 900 mg IV 7 days later (week 3), followed by 900 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 20 to less than 30 kg: 600 mg IV once every 7 days for 2 weeks, then 600 mg IV 7 days later (week 3), followed by 600 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 10 to less than 20 kg: 600 mg IV once every 7 days on week 1, then 300 mg IV 7 days later (week 2), followed by 300 mg IV every 2 weeks thereafter.
Children ages 6 and older weighing 5 to less than 10 kg: 300 mg IV once every 7 days on week 1, then 300 mg IV 7 days later (week 2), followed by 300 mg IV every 3 weeks thereafter.
Adjust-a-dose: Give a supplemental dose within 60 minutes after each plasmapheresis or plasma exchange session. If the most recent dose was 300 mg, give 300-mg supplemental dose. If the most recent dose was 600 mg or more, give 600-mg supplemental dose. For patients receiving fresh frozen plasma, if the most recent dose was 300 mg or more, give 300-mg supplemental dose 1 hour before each unit of fresh frozen plasma. In a patient receiving concomitant IV immunoglobulin treatment, refer to the manufacturer's instructions for supplemental eculizumab dose requirements and timing.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
emtricitabine-rilpivirine-tenofovir alafenamide
Odefsey
Pharmaceutical company: Gilead Sciences
NEW INDICATION & DOSAGE
HIV-1 infection as initial therapy in patients with no antiretroviral treatment history and HIV-1 RNA of 100,000 copies/mL or less; or to replace a stable antiretroviral regimen in patients who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components
Children ages 6 and older weighing at least 25 kg: 1 tablet PO daily with a meal.
Adjust-a-dose: For patients on hemodialysis, give 1 tablet daily; give after hemodialysis on dialysis days. This drug isn't recommended for patients with creatinine clearance of less than 30 mL/minute or in patients with chronic kidney disease who aren't receiving long-term dialysis.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
epinephrine
Neffy
Pharmaceutical company: ARS Pharma
NEW AVAILABLE FORM
Nasal spray: 1 mg/0.1 mL per single-dose spray
NEW INDICATION & DOSAGE
Type I allergic reactions, including anaphylaxis
Adults and children ages 4 and older weighing 15 to less than 30 kg: One spray (1 mg) into one nostril. If there is no clinical response or worsening symptoms, repeat the dose after 5 minutes in the same nostril.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
furosemide
Furoscix
Pharmaceutical company: scPharmaceuticals
NEW INDICATION & DOSAGE
Edema in patients with chronic kidney disease, including the nephrotic syndrome
Adults: Subcutaneous on-body infusor with prefilled cartridge preprogrammed to deliver 30 mg over first hour, followed by 12.5 mg per hour for subsequent 4 hours. Total dose, 80 mg over 5 hours.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
glucagon
Baqsimi
Pharmaceutical company: Amphastar Pharmaceuticals
NEW INDICATION & DOSAGE
Severe hypoglycemia in patients with diabetes
Children ages 1 and older: 3 mg (one actuation of intranasal device) into one nostril. If there is no response after 15 minutes, the dose may be repeated.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
pembrolizumab
Keytruda
Pharmaceutical company: Merck
NEW INDICATION & DOSAGE
First-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy
Adults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in patients without disease recurrence. Give before trastuzumab and chemotherapy, when given the same day.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
tenecteplase
TNKase
Pharmaceutical company: Genentech
NEW INDICATION & DOSAGE
Acute ischemic stroke
Adults weighing 90 kg or more: 25 mg (5 mL) by IV bolus over 5 seconds.
Adults weighing 80 to less than 90 kg: 22.5 mg (4.5 mL) by IV bolus over 5 seconds.
Adults weighing 70 to less than 80 kg: 20 mg (4 mL) by IV bolus over 5 seconds.
Adults weighing 60 to less than 70 kg: 17.5 mg (3.5 mL) by IV bolus over 5 seconds.
Adults weighing less than 60 kg: 15 mg (3 mL) by IV bolus over 5 seconds.
Adjust-a-dose: Begin treatment as soon as possible and within 3 hours of the onset of stroke symptoms.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
tesamorelin acetate
Egrifta WR
Pharmaceutical company: Theratechnologies
NEW AVAILABLE FORM
Injection (Egrifta WR):11.6-mg vials
NEW INDICATION & DOSAGE
Reduction of excess abdominal fat in patients infected with HIV-1 with lipodystrophy
Adults: Inject 1.28 mg (0.16 mL) subcut once daily in abdomen.
Released: May 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.